… -dose interleukin-2 (IL-2) either alone or in combination with interferon alfa-2b (IFN; Schering…
metastatic renal cell carcinoma, the IL-2 Working Group initiated a randomized phase II trial. …

… In this study, we combined temozolomide with interferon alfa-2b and, separately, with …
The objectives of this randomized phase II, two-center study were to determine response rates, …

… There is an ongoing randomized phase II trial of sorafenib versus IFN-α in untreated RCC
patients 22 ; if the median PFS of sorafenib-treated patients in that trial is substantially less …

… Grade 3 toxicities including anorexia, dyspnea, fatigue, myalgia, and pain occurred with
similar frequencies in the two study arms. One patient on the Bev alone arm developed grade 4 …

… To explore the clinical activity of combined sorafenib and interferon therapy in advanced
renal carcinoma, we performed a phase II study in patients with clear-cell histology and no prior …

… alfa has been established in treating advanced melanoma and renal cell carcinoma (RCC)
patients. We conducted a phase I/II study to … -weekly pegylated interferon alfa-2b (IFNα-2b) in …

… alfa responses were lower in this study compared with historical data, post-treatment alfa …
ISGs in whole blood was seen with alfa than lambda in this study (data not shown), consistent …

… of IL-2 were investigated. RRs of up to 56% were achieved in the initial phase II studies with
… RRs exceeding 50% were seen often in phase II studies incorporating cisplatin, IFN-α, and …

… in phase II trials motivated the present study. … This study comprised patients randomly
assigned to gemcitabine or best … Clinic published data of a phase II trial of 43 patients undergoing …

… In comparison, only two thirds of … 2 /d, resulting in a mean delivered dose of 18 × 10 6 U/m
2 /d (10% decrease from the planned dose). Moreover, only 2% of patients in the current study …